Effect of introducing high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children
This is the main finding of a recent article based on data from The Streptococcus pneumoniae Invasive Disease network (SpIDnet).
Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children
The study compares the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001 in Germany.
Decline in early childhood respiratory tract infections in the norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination
The study design and analysis controlled for influence of potentially confounding trends, such as improvement of day-care carriage and decreasing prevalence of smoking during the study period.
Surveillance of invasive pneumococcal disease in Europe
Pneumococcal meningitis in French children before and after the introduction of pneumococcal conjugate vaccineArchived
In the context of an active nationwide surveillance network, this study describes pneumoccocal meningitis in children aged from 1 day to 15 years during a 8 year study period (2001-2008) in France. 951 pneumoccocal meningitis cases were reported among 3312 children with bacterial meningitis. T
Serotype replacement in disease after pneumococcal vaccinationArchived
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.